Last reviewed · How we verify

NCT03152539: MAP-VS

Development of MRI Protocols and Associated Explorations (EEG, NIRS) in Healthy Volunteers

Completed NA Last updated 20 October 2021
What this trial tests

NA trial testing MRI in Magnetic Resonance Imaging in 733 participants. Completed in 8 July 2021.

Timeline
7 June 2012
Primary endpoint
8 July 2021
8 July 2021

Quick facts

Lead sponsorUniversity Hospital, Grenoble
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationnon randomized
Designsingle group
Maskingnone
Primary purposebasic science
Enrollment733
Start date7 June 2012
Primary completion8 July 2021
Estimated completion8 July 2021
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

University Hospital, Grenoble

Who can join

18 and older, any sex, with Magnetic Resonance Imaging. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The main objective of the studies that will be carried out on volunteer patients who have given their consent will be the development and optimization of the sequence parameters or the design of the stimulation paradigms in order to optimize the quality and Relevance of the images realized taking into account anatomical, functional or metabolic parameters. These adjustments will be carried out without interfering with the management of voluntary patients

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of MRI

Trials testing the same drug.

Other recruiting trials for Magnetic Resonance Imaging

Currently open trials in the same condition.

Other University Hospital, Grenoble trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03152539.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing